There’s been a steady stream of figures since the pandemic began, each laying bare what many people have seen first-hand – the impact on health services.
This autumn the chancellor Rishi Sunak will set out the Government’s spending priorities. Here’s why it’s time to invest in cancer services and research.
Campaigner Patrick McGuire writes to Boris Johnson about honouring his manifesto commitments in the upcoming Comprehensive Spending Review.
We’ve estimated it will cost HEE between £142 million and £260 million more than it already invests to grow the key cancer professions by 45%.
Cancer services are beginning to get up and running across the country, but we’re still a long way from either restoring capacity or addressing the backlog of people waiting for tests and treatment.
A new breed of targeted cancer drug has been approved for NHS use in England. But drugs like larotrectinib also pose unique and complex challenges for the NHS, which have been exacerbated by the COVID-19 pandemic.
Cancer services have been severely disrupted across the UK, from screening to treatment and care.
What do the latest recommendations from Sir Mike Richards mean for screening in England? We take a look.